Heart surgery without a heart-lung machine - 18/11/2026 HeartGate: the safe gateway to the heart For patients with advanced heart failure, a mechanical heart pump can offer a life-saving alternative to heart transplants. As part of the HeartGate project, researchers at the University Medical Center Freiburg are developing an innovative implantation system to insert a heart pump directly into a beating heart. https://www.gesundheitsindustrie-bw.de/en/article/news/heartgate-safe-gateway-heart
Press release - 17/11/2026 When Brake Cells Become Killer Cells: Double Honor for DKFZ Researcher Julius Michel Julius Michel, a postdoctoral researcher at the German Cancer Research Center, has received two awards: the Craig Tendler Award for Myeloma Research from the American Society of Hematology - awarded for the first time and accompanied by a $10,000 prize - as well as another award from the society.https://www.gesundheitsindustrie-bw.de/en/article/press-release/when-brake-cells-become-killer-cells-double-honor-dkfz-researcher-julius-michel
Press release - 16/11/2026 AI and life sciences: two new research training groups at Universität Heidelberg Heidelberg University has been successful in the current approval round of the German Research Foundation with two applications for the funding of Research Training Groups. RTG 3251 “From Omics to Mechanisms”, which is located in the life sciences, seeks to develop new methods of obtaining, analyzing and interpreting extensive biological datasets. Research Training Group 3270 “Generative AI in the Sciences” focuses on artificial intelligence.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-and-life-sciences-two-new-research-training-groups-universitaet-heidelberg
Press release - 12/11/2026 DKFZ Sets Records for ERC Synergy Grants A historic success for the German Cancer Research Center (DKFZ): Four DKFZ researchers are receiving one of the prestigious ERC Synergy Grants this year—more than ever before at a single institution in a single funding round. Three of the four international research consortia are coordinated by the DKFZ. In total, the projects will receive approximately 44.5 million euros, of which about 13.7 million euros will go to the DKFZ.https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-sets-records-erc-synergy-grants
Press release - 12/11/2026 Universität Heidelberg and Harvard university mark the launch of their strategic partnership With a strategic partnership, Heidelberg and Harvard University are expanding their academic relationships, strengthening transatlantic networks and promoting excellent research.https://www.gesundheitsindustrie-bw.de/en/article/press-release/universitaet-heidelberg-and-harvard-university-mark-launch-their-strategic-partnership
Press release - 11/11/2026 Spine tumor surgery: Better preparation with a digital twin How can complex spinal tumor surgeries be planned and prepared more effectively in the future? As part of the IntelliSpine-Recon collaborative project, researchers will develop, among other innovations, a digital twin of the spine and a virtual training environment for surgeons. The junior research consortium, coordinated by the Heidelberg Faculty of Medicine at Heidelberg University, is being carried out in partnership with the KIT. https://www.gesundheitsindustrie-bw.de/en/article/press-release/spine-tumor-surgery-better-preparation-digital-twin
Press release - 09/11/2026 Mirco Friedrich Receives the Peter and Traudl Engelhorn Foundation Award Mirco Julian Friedrich, a physician and cancer researcher at the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Research Institute, and Heidelberg University Hospital (UKHD), is being honored for his outstanding research on the aging immune system and the immune response to blood cancer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mirco-friedrich-receives-peter-and-traudl-engelhorn-foundation-award
Press release - 04/11/2026 Hahn-Schickard Transfers Joint Venture Shares to Endress+Hauser Five years after the companies were jointly founded, the Endress+Hauser Group has acquired the shares in Endress+Hauser BioSense previously held by Hahn-Schickard. This move marks an important milestone in the successful transfer of microfluidic technologies from research to industrial applications. The technological partnership will continue.https://www.gesundheitsindustrie-bw.de/en/article/press-release/hahn-schickard-transfers-joint-venture-shares-endress-plus-hauser
Press release - 04/11/2026 Molecular guardian inhibits aggressive brain tumor's ability to switch between identities One of the reasons for the high aggressiveness of glioblastomas is their remarkable adaptability. A team led by scientists from the German Cancer Research Center (DKFZ), the EMBL, HITBR*, and the Wellcome Sanger Institute, Cambridge, now describes how glioblastoma cells switch between different states. At the same time, they identified a key factor that, acting as a guardian of cell identity, limits this adaptability.https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-guardian-inhibits-aggressive-brain-tumors-ability-switch-between-identities
Robotics in medicine: initial trials of HASEL technology - 04/11/2026 Using artificial muscles to reduce uncontrolled tremors For people with tremors, even simple everyday tasks can become a challenge. Researchers from Stuttgart and Tübingen are developing a novel assistive system designed to actively suppress these involuntary movements. Initial tests using artificial muscles based on HASEL technology have shown promising results – but there is still a long way to go before the technology is ready for everyday use.https://www.gesundheitsindustrie-bw.de/en/article/news/using-artificial-muscles-reduce-uncontrolled-tremors
Press release - 02/11/2026 Stem Cells in Deep Sleep as a Secret Reserve Researchers at the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have discovered a group of particularly long-lived blood stem cells in mice. These cells remain in a dormant state for an exceptionally long time while retaining their ability to generate new blood cells. This newly discovered cell population may be responsible for sustaining blood regeneration and immune defense throughout a mouse’s entire life.https://www.gesundheitsindustrie-bw.de/en/article/press-release/stem-cells-deep-sleep-secret-reserve
Press release - 02/11/2026 Heidelberger researchers receive Else Kröner memorial fellowships for projects on kidney disease and AI-based diagnostics Why do certain congenital kidney disorders vary so widely in severity among affected individuals? Can AI improve breast cancer diagnostics? These are the questions being addressed in current projects by two early-career researchers at the Heidelberg Faculty of Medicine at Heidelberg University. https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberger-researchers-receive-else-kroner-memorial-fellowships-projects-kidney-disease-and-ai-based-diagnostics
Press release - 29/10/2026 New Approach Could Make Immunotherapy for Blood Cancer More Precise Researchers at the Faculty of Medicine – University of Freiburg have developed a new approach to specifically target an aggressive form of blood cancer while better sparing healthy immune cells. In what is known as T-cell acute lymphoblastic leukemia (T-ALL), cancer cells develop from the body’s own immune defense cells. This complicates treatment, as immunotherapies studied to date can also destroy healthy immune cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-could-make-immunotherapy-blood-cancer-more-precise
Press release - 29/10/2026 VUSE XR closes €1.2 million pre-seed round to scale enterprise mixed reality training VUSE XR today announced the closing of a €1.2 million pre-seed financing round led by IACD, a Düsseldorf-based business angel network. The company develops the VUSE XR Hub, an enterprise software solution for creating and deploying mixed reality training for industrial and life sciences companies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vuse-xr-closes-euro-12-million-pre-seed-round-scale-enterprise-mixed-reality-training
Press release - 28/10/2026 A Discovery in Freiburg Makes Cancer Immunotherapy Better Tolerated A discovery made in Freiburg opens up new treatment options for cancer patients worldwide: Researchers at the Medical Center – University of Freiburg have discovered how severe side effects of cancer immunotherapies can be alleviated using a specialized cell therapy involving treated white blood cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/discovery-freiburg-makes-cancer-immunotherapy-better-tolerated
Press release - 26/10/2026 Multiple sclerosis: New treatment significantly reduces relapses A new treatment could improve care for people with relapsing multiple sclerosis (MS). In two international studies involving a total of 2,007 patients, remibrutinib reduced the annualized relapse rate by 31% to 35% compared with an established MS therapy. New inflammatory brain lesions were also significantly less frequent. In addition, there are indications that the treatment may slow the progression of physical disability.https://www.gesundheitsindustrie-bw.de/en/article/press-release/multiple-sclerosis-new-treatment-significantly-reduces-relapses
Press release - 20/10/2026 How randomness makes artificial vision more reliable Humans are usually remarkably good at recognising objects, even under poor viewing conditions. Artificial vision systems, by contrast, reach their limits more quickly when images are distorted or unfamiliar. Researchers at the Hertie Institute for Clinical Brain Research (HIH) have now investigated what artificial vision systems can learn from the brain.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-randomness-makes-artificial-vision-more-reliable
Prime Vector Technologies is developing a new vaccine platform - 20/10/2026 The ORF platform – one virus, many possibilities Many vaccines effectively deliver an antigen to the desired target site. But what if, at the same time, the immune system could be specifically orchestrated to build broad and comprehensive protection? This idea led to the development of a novel vector platform based on the Orf virus. The work was carried out by the Tübingen-based start-up Prime Vector Technologies.https://www.gesundheitsindustrie-bw.de/en/article/news/orf-platform-one-virus-many-possibilities
Press release - 19/10/2026 New Biotech Master’s Degree Launches at Ulm University: Pharmaceutical and Molecular Biotechnology How do RNA-, protein- or stem cell-based therapies work? How can data science methods from bioinformatics and artificial intelligence be used to develop new pharmaceutical active substances? Students at Ulm University are learning this in the new master’s programme in Pharmaceutical and Molecular Biotechnology (PMB).https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-biotech-masters-degree-launches-ulm-university-pharmaceutical-and-molecular-biotechnology
Press release - 16/10/2026 A new approach to osteoporosis treatment Disabling a bone formation inhibiting protein molecule How can the human body be stimulated to build more bone, thus helping those affected by osteoporosis? Researchers in Ulm have investigated the role played by the protein molecule Axl in this process. Their efforts were successful: in a study, they demonstrated that Axl inhibits bone formation – and that cells produce significantly more bone tissue when the molecule is blocked using medication. There are no discernible harmful side effects. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-osteoporosis-treatment-disabling-bone-formation-inhibiting-protein-molecule
Press release - 16/10/2026 Epilepsy: AI Aims to Improve Treatment with Brain Pacemakers About 250,000 people in Germany live with epilepsy that does not respond adequately to medication. How can their treatment be further improved with a brain pacemaker? As part of the CLOUDIA research project, the Medical Center – University of Freiburg is now collaborating with a medical technology company to develop an AI-supported assistance system for analyzing long-term brain activity data.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epilepsy-ai-aims-improve-treatment-brain-pacemakers
Press release - 15/10/2026 Four Million Euros in EU Funding to Improve Prostate Cancer Care A European research consortium led by the German Cancer Research Center (DKFZ) aims to fundamentally improve the diagnosis and treatment of prostate cancer using AI agents, big data, and patient-centered clinical decision support. The central goal is to detect aggressive tumors early and accurately, reduce unnecessary interventions, and tailor treatment decisions more closely to the individual patient.https://www.gesundheitsindustrie-bw.de/en/article/press-release/four-million-euros-eu-funding-improve-prostate-cancer-care
Event - 18/11/2026 Match Arena Stuttgart, Networking Event https://www.gesundheitsindustrie-bw.de/en/event/match-arena-en
Press release - 08/10/2026 High iron levels may promote the mobility of brain tumor cells Iron is essential for healthy cells. Cancer cells also require this trace element. Researchers in Freiburg have now found evidence that high levels of iron directly in the tumor microenvironment promote the spread of certain cells in a particularly aggressive type of brain tumor known as glioblastoma. In the long term, iron metabolism could therefore serve as a target for more precisely influencing particularly invasive tumor cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-iron-levels-may-promote-mobility-brain-tumor-cells
A revolution in glass processing technology for the medical technology sector - 07/10/2026 The Freiburg-based start-up Glassomer is rethinking materials Glassomer has developed an innovative process for producing pure quartz glass. The result is geometrically complex glass components with micrometre-level precision that can be reproduced consistently at a fraction of the energy cost of conventional glass-melting processes. The company focuses in particular on customised products for diagnostic, therapeutic and microfluidic applications.https://www.gesundheitsindustrie-bw.de/en/article/news/freiburg-based-start-glassomer-rethinking-materials